(Q34094755)

31 July 2017

1 reference

title

Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions (English)

1 reference

31 July 2017

0 references

2

Magnus Simrén

1 reference

31 July 2017

Lena Ohman

1

1 reference

PubMed ID

20101257

31 July 2017

language of work or name

English

0 references

publication date

26 January 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

31 July 2017

1 reference

31 July 2017

7

1 reference

31 July 2017

3

1 reference

31 July 2017

163-173

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2010.4

31 July 2017

0 references

cites work

Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

New insights into the pathogenesis and pathophysiology of irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Altered rectal perception in irritable bowel syndrome is associated with symptom severity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Altered small bowel motility in irritable bowel syndrome is correlated with symptoms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Functional bowel disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

A case for an immunological basis for irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Symptoms of irritable bowel syndrome in ulcerative colitis in remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Celiac disease and irritable bowel-type symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Postinfectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Postinfectious irritable bowel syndrome--a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The role of psychological and biological factors in postinfective gut dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Post-infectious irritable bowel syndrome in patients with Shigella infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Irritable bowel syndrome--post salmonella infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

To "lump" or to "split" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Review article: an integrated approach to the irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Epidemiology and the natural course of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Ulcerative colitis and irritable bowel syndrome: relationships with quality of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Increased mast cells in the irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Role for protease activity in visceral pain in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Activation of the mucosal immune system in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Immune dysfunction in patients with functional gastrointestinal disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Immune activation in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Mucosal cytokine imbalance in irritable bowel syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Public speaking stress-induced neuroendocrine responses and circulating immune cell redistribution in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Natural killer cell function and psychological distress in women with and without irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

CD4+CD25high regulatory cells in human peripheral blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

T-cell activation in patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

CD4+CD25+ regulatory T cells in irritable bowel syndrome patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

B-cell activation in patients with irritable bowel syndrome (IBS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Food hypersensitivity and irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Use and abuse of hydrogen breath tests

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Abolishment of TNBS-induced visceral hypersensitivity in mast cell deficient rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The usefulness of ultrasound diagnosis specifically in taeniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

A Pilot Study of Fecal Serine-Protease Activity: A Pathophysiologic Factor in Diarrhea-Predominant Irritable Bowel Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Food intolerance and the irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.4

Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study

31 March 2020

1 reference

12 December 2020

A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea

1 reference

12 December 2020

The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases

1 reference

12 December 2020

A pilot study of colonic B cell pattern in irritable bowel syndrome

1 reference

12 December 2020

TRPV1-expressing sensory fibres and IBS: links with immune function.

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2010.4

1 reference

release_wp5fgbskwrhfphowcopdrd5g3m

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wp5fgbskwrhfphowcopdrd5g3m

24 November 2022

mapped directly with Wikidata item

PubMed ID

20101257

1 reference

PubMed ID

20101257